Navigation Links
UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
Date:8/6/2013

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Columbia on behalf of investors who purchased Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NasdaqGM: VNDA) stock between December 18, 2012 and June 18, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/vanda-pharmaceuticals-vnda/

The complaint alleges that defendants violated federal securities laws by issuing materially false and misleading statements and/or failing to disclose materially adverse facts concerning the Company's Phase III testing of the drug Tasimelteon. In particular, it is alleged that, in the middle of the Phase III studies, Vanda altered the primary endpoint to one never before used in a sleep-drug clinical trial—and not endorsed by the FDA—when data suggested the original endpoint would not be met.

On June 19, 2013, an article was published on thestreet.com, questioning the efficacy of Vanda's study, noting that the study not only changed multiple times, but that it replaced the primary endpoint just a month before study results were announced. On the news, shares of Vanda closed at $8.51 per share on June 19, 2013, a drop of more than 20% from the previous day.

If you suffered a loss in Vanda you have until August 24, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/vanda-pharmaceuticals-vnda/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (866) 367-6510
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Hospira to Present at Upcoming Investor Conferences
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
7. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
8. MDHI Provides Investor Update -- Provides Business Model Overview -- Discusses Upcoming Profitability
9. Delcath To Present At Upcoming Investor Conferences
10. Uroplasty To Participate In Two Upcoming Conferences
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the ... monitoring solutions, announced today the launch of a redesigned corporate website, 800response.com ... aesthetic, fully responsive design, and an enhanced search directory for businesses and advertising ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Beyond Our ... fulfilled life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, ... across the country. , Lawrence shares, “The problem with becoming a greater man of ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared leadership between physicians ... effective, very effective, or effective by 85% of respondents, according to the recent ... Reports are based on surveys of the NEJM Catalyst Insights Council, a qualified ...
Breaking Medicine News(10 mins):